SOMAÍ To Enter Polish Medical Cannabis Market Via Cosma


20-Year Pro Trader Reveals His "MoneyLine"

Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.


SOMAÍ Pharmaceuticals Unipessoal LDA has entered into a two-year supply agreement with a Polish distributor Cosma Cannabis. Cosma produces medical-grade cannabis products for importation and distribution across Poland. The contract represents 1 million euros ($1.08 million) in sales for SOMAÍ's 2024 goals to develop the fast-emerging medical cannabis markets of Poland.

“We are very proud that Cosma has chosen SOMAÍ Pharmaceuticals as their preferred manufacturer to penetrate the Polish market with our extract formulations,” stated SOMAÍ Pharmaceuticals CEO and chairman Michael Sassano. “Being one of the first manufacturers in a large market with positive regulatory reforms must have good partners like Cosma that can effectively educate and represent our current and future product offerings.”

By the terms of the agreement, SOMAÍ has agreed to supply medical cannabis products to Cosma for distribution in Poland under the trademark of Cosma. Additionally, Cosma will be granted marketing authorization to supply, market, and distribute the products within the designated territory. It has been stipulated in the agreement that Cosma will carry out the distribution of the products in compliance with the agreed-upon terms and conditions.

The medical cannabis products distributed under the agreement consist of oil drops in various ratios of THC/CBD, including 25:1, 10:10, 2.5:25, and 20:1.

“Initiation cooperation with SOMAÍ has allowed us to offer innovative medicinal substances in the Polish market. We plan to develop products dedicated to eastern Europe patients jointly. Due to the unique composition and the use of particular ingredients in these products, their absorption by the human body will be much greater than that of competitor’s products.” – stated Lukasz Kreski, chairman and co-founder of COSMA. “We also plan to begin joint clinical research and studies in pain management, inflammatory conditions, neurodegenerative diseases, and oncology.”

Photo by Esteban López on Unsplash


20-Year Pro Trader Reveals His "MoneyLine"

Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.


ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

Posted In: CannabisNewsMarketsCosma CannabisLukasz KreskiMichael SassanopremiumSOMAÍ Pharmaceuticals